oral in Medical Technology
Navigation Links
oral in Medical Technology
... at the cellular level of the hair follicle. These oral medications also may be an option for women who ... and works best in conjunction with topical or oral medications to prevent further hair loss.
... the death of a loved one, starting or stopping oral contraceptives, iron deficiency, and chronic ...
... closely by your health care provider and the oral steroids should be reduced slowly. Deaths due to ... have occurred during and after switching from oral steroids to inhaled steroids. Tell your health ... AEROLIZER is not a substitute for inhaled or oral corticosteroids and, in the treatment of asthma, ...
... even for patients who are restricted from oral medication. Patients appear to tolerate the ... of sufentanil NanoTabs sublingually for oral transmucosal absorption. Sufentanil is a high ... to its short IV plasma half-time. In the NanoTab oral transmucosal dosage form, sufentanil demonstrates ...
... with eight presentations (including three oral talks and two late-breaking posters) during the ... anti-obesity therapeutic strategy. In the oral presentation titled "ISIS 388626, an SGLT2 ... from its obesity drug discovery program. In an oral presentation, Isis reported that antisense ...
... rhinitis and asthma. orBec(R) is formulated for oral administration as a single product consisting of ... trial in the prevention of acute GVHD. oral BDP may also have application in treating other ... (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of ...
... trial evaluating the safety and efficacy of oral torezolid (TR-701), its investigational ... "I was impressed by the rapid clinical effect of oral torezolid in curing severe skin infections caused ... antibiotic, but the trial results indicate that oral torezolid successfully treated these severe ...
... in a more efficient way compared to current oral standard treatment. Inhaled L-CsA has a favorable ... These results are significantly lower compared to oral therapy. In comparison, oral CsA (Neoral(R)) therapy in lung transplant ...
... researchers discovered that when they utilized oral chemotherapy agent capecitabine, also known by ... The exploration of low-dose, long-term oral chemotherapy agents in adjuvant (i.e. follow-up) ... Capecitabine was the first FDA-approved oral chemotherapy treatment, gaining approval for ...
... oral CCR9 Antagonist Demonstrates Clinical Efficacy ... Radcliffe Hospital, Oxford University , in an oral session today. The study, "PROTECT-1 ... versus 40 percent for placebo (p=0.029). In his oral presentation, Dr. Keshav further noted that ...
... myeloma patients were presented today in an oral session by Sundar Jagannath, M.D., Chief of the ... These data were presented by Dr. Jagannath in an oral presentation titled " Final results of ... proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective ...
... analyses of these data indicated that once-daily oral dosing with linaclotide, across a range of doses, ... ) The data presented today in an oral presentation ( Abstract 157: Effect of ... Results from a Phase 2b Study of Linaclotide , an oral presentation by Jeffrey Johnston, M.D., F.A.C.P., ...
... for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the ... Society of Clinical Oncology (ASCO) in an oral presentation titled "Phase II results of Study ... proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective ...
... will be randomly assigned (2:1) to receive either oral talactoferrin or placebo in additional to ... with carboplatin and paclitaxel plus either oral talactoferrin or placebo. Agennix has received ... had failed standard therapy. Patients receiving oral talactoferrin in this Phase II trial had a median ...
... torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th ... as follows: Saturday, May 16th oral Presentation - Lecture Hall 3a (14:54 - 15:06) ... P 1090 : The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug ...
... (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with ... today for the first time, as a late-breaking oral presentation at the 61st Annual Meeting of the ... an important step towards delivering an oral therapy to people living with this condition." ...
... of the EPIC3 Cirrhosis Maintenance Trial. oral presentation at: 44th European Association for ... Final Results of the SUCCESS Study. oral presentation at: 44th annual meeting of the ... 3 Chronic Hepatitis C Patients (REDD 2/3 Trial). oral presentation at: 44th European Association for ...
... C virus (HCV)(1). The study combined two oral DAAs, R7227 (also known as ITMN-191) and R7128, ... the first to investigate the combination of two oral antiviral medicines in the absence of interferon ... for the first time that the combination of an oral protease inhibitor and ...
... 3 results were the subject of two late-breaker oral presentations today in Copenhagen at the 44th ... of 180 mcg - with all patients receiving daily oral ribavirin concomitantly. In ACHIEVE 2/3, 933 ... web site at www.hgsi.com . To view the EASL oral presentation reporting results of the ACHIEVE 1 ...
... study to investigate the combination of two oral antiviral medicines in the absence of weekly ... primary focus is on the development of oral therapeutics for the treatment of hepatitis C ... developing three product candidates. R7128, an oral treatment for chronic HCV infection, has ...
... CEST (7 a.m. PDT) on Friday, April 24. In an oral presentation, Anadys will present in vitro data ... ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed ... with the potential for once-daily or twice-daily oral dosing. In the preclinical program, ANA598 ...
... study showed boceprevir, its investigational oral hepatitis C protease inhibitor, in combination ... Annual Meeting; April 22-26, Copenhagen, Denmark; oral presentation, Abstract No. 4. 3. ... Annual Meeting; April 22-26, Copenhagen, Denmark; oral presentation, Abstract No. 126. 5. Reesink ...
... less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's ... of losing share upon the launch of either oral cladribine or fingolimod, as more physicians cite ...
... for Ophena(TM) , the most advanced estrogen-free oral therapy currently in development for the ... are being treated with either a 60mg once daily oral dose of Ophena(TM) or placebo over the 12-week ... receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary ...
... in postmenopausal patients when compared to oral delivery, a new study suggests. The study was ... activity before and after administration of oral or transdermal estrogen for a period of eight ... "a significant acceleration" of clotting after oral estrogen therapy, but no significant change after ...
... 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a ... III clinical trial to study the effects of an oral mTOR inhibitor in advanced RCC patients whose ... fungal infections should not receive Afinitor. oral ulceration is a common side effect with Afinitor. ...
... ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has ... (PK) and Pharmacodynamics (PD) of oral Insulin Formulations in Subjects with Type 2 ... will highlight the successful results from its oral insulin trials on type 2 diabetes patients ...
... to oxaliplatin. oral Picoplatin : In November, the Company announced ... results from a Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid ... dose-dependent plasma exposure when given by the oral route, indicating sufficient bioavailability to ...
... SGP ) Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were ... dose-ranging trial assessing both oral loading doses as well as maintenance doses of ... PCI was planned, and randomized to one of three oral loading doses of TRA (10mg, 20mg or 40mg) or ...
... a phase one clinical trial of AOBO-001, an oral capsule developed from traditional Chinese ... Company currently manufactures and markets the oral capsule in China under the Cease Enuresis oral Capsule brand, which was approved by China's ...
... NKTR-118, a peripheral opioid antagonist, is an oral once-a-day investigational drug to treat OIC, the ... or reversal of analgesia. There are no oral therapies to date that have demonstrated as much ... this heterogeneous population of patients." oral NKTR-118 combines Nektar's advanced small ...
... closely by your health care provider and the oral steroids should be reduced slowly. Deaths due to ... have occurred during and after switching from oral steroids to inhaled steroids. Tell your health ... AEROLIZER is not a substitute for inhaled or oral corticosteroids and, in the treatment of asthma, ...
Teeth and Gums Also Benefit from the Healing Power of Aloe Vera
... as toothpaste, which is to eliminate pathogenic oral microflora -- disease-causing bacteria -- in the ... have a number of choices when it comes to their oral health, and aloe vera is one of them," says AGD ... are interested in a more alternative approach to oral hygiene, they should speak with their dentist to ...Is Obesity an Oral Bacterial Disease?
... have focused on the possible role of oral bacteria as a potential direct contributor to ... of future research, is the possibility that oral bacteria may participate in the pathology that ... research and increasing knowledge to improve oral health, (2) supporting ...... even for patients who are restricted from oral medication. Patients appear to tolerate the ... of sufentanil NanoTabs sublingually for oral transmucosal absorption. Sufentanil is a high ... to its short IV plasma half-time. In the NanoTab oral transmucosal dosage form, sufentanil demonstrates ...
Spherix Announces Positive Phase 2 Study Results
... multicenter study evaluated the minimum oral dose of Naturlose capable of causing a beneficial ... (within the prior 3 months) of treatment with any oral or injectable anti-diabetic treatment were ... with type 2 diabetes underwent separate 3-hour oral glucose and tagatose tolerance tests. The ...... with eight presentations (including three oral talks and two late-breaking posters) during the ... anti-obesity therapeutic strategy. In the oral presentation titled "ISIS 388626, an SGLT2 ... from its obesity drug discovery program. In an oral presentation, Isis reported that antisense ...
... rhinitis and asthma. orBec(R) is formulated for oral administration as a single product consisting of ... trial in the prevention of acute GVHD. oral BDP may also have application in treating other ... (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of ...
... trial evaluating the safety and efficacy of oral torezolid (TR-701), its investigational ... "I was impressed by the rapid clinical effect of oral torezolid in curing severe skin infections caused ... antibiotic, but the trial results indicate that oral torezolid successfully treated these severe ...
Boehringer Ingelheim Unveils Diabetes Pipeline
... Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in ... DPP-4 inhibitors are a newer class of oral hypoglycemics that target the incretin hormones ... Boehringer Ingelheim and is being developed as an oral once-daily tablet for the treatment of type 2 ...... in a more efficient way compared to current oral standard treatment. Inhaled L-CsA has a favorable ... These results are significantly lower compared to oral therapy. In comparison, oral CsA (Neoral(R)) therapy in lung transplant ...
... researchers discovered that when they utilized oral chemotherapy agent capecitabine, also known by ... The exploration of low-dose, long-term oral chemotherapy agents in adjuvant (i.e. follow-up) ... Capecitabine was the first FDA-approved oral chemotherapy treatment, gaining approval for ...
... oral CCR9 Antagonist Demonstrates Clinical Efficacy ... Radcliffe Hospital, Oxford University , in an oral session today. The study, "PROTECT-1 ... versus 40 percent for placebo (p=0.029). In his oral presentation, Dr. Keshav further noted that ...
... myeloma patients were presented today in an oral session by Sundar Jagannath, M.D., Chief of the ... These data were presented by Dr. Jagannath in an oral presentation titled " Final results of ... proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective ...
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
... in Orlando, Florida. Data were presented in both oral discussion and poster sessions. (Logo: ... ) ENMD-2076, a small molecule, oral kinase inhibitor that targets Aurora A and other ... other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the ...... analyses of these data indicated that once-daily oral dosing with linaclotide, across a range of doses, ... ) The data presented today in an oral presentation ( Abstract 157: Effect of ... Results from a Phase 2b Study of Linaclotide , an oral presentation by Jeffrey Johnston, M.D., F.A.C.P., ...
... for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the ... Society of Clinical Oncology (ASCO) in an oral presentation titled "Phase II results of Study ... proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective ...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... including digoxin, metformin, omeprazole, and an oral contraceptive (containing 0.03 mg ... in two divided doses. Vimpat(R) is available as oral tablets and as an intravenous (IV) infusion to ... for infusion is an alternative for patients when oral administration is temporarily not feasible. ...... will be randomly assigned (2:1) to receive either oral talactoferrin or placebo in additional to ... with carboplatin and paclitaxel plus either oral talactoferrin or placebo. Agennix has received ... had failed standard therapy. Patients receiving oral talactoferrin in this Phase II trial had a median ...
... torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th ... as follows: Saturday, May 16th oral Presentation - Lecture Hall 3a (14:54 - 15:06) ... P 1090 : The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug ...
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
... completed in May 2008. oral Picoplatin In April, final data from a Phase 1 clinical study of an oral formulation of picoplatin in patients with solid ... Results showed that the bioavailability of oral picoplatin is nearly 100 percent at doses of 50 ...... (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with ... today for the first time, as a late-breaking oral presentation at the 61st Annual Meeting of the ... an important step towards delivering an oral therapy to people living with this condition." ...
... of the EPIC3 Cirrhosis Maintenance Trial. oral presentation at: 44th European Association for ... Final Results of the SUCCESS Study. oral presentation at: 44th annual meeting of the ... 3 Chronic Hepatitis C Patients (REDD 2/3 Trial). oral presentation at: 44th European Association for ...
... C virus (HCV)(1). The study combined two oral DAAs, R7227 (also known as ITMN-191) and R7128, ... the first to investigate the combination of two oral antiviral medicines in the absence of interferon ... for the first time that the combination of an oral protease inhibitor and ...
... 3 results were the subject of two late-breaker oral presentations today in Copenhagen at the 44th ... of 180 mcg - with all patients receiving daily oral ribavirin concomitantly. In ACHIEVE 2/3, 933 ... web site at www.hgsi.com . To view the EASL oral presentation reporting results of the ACHIEVE 1 ...
... study to investigate the combination of two oral antiviral medicines in the absence of weekly ... primary focus is on the development of oral therapeutics for the treatment of hepatitis C ... developing three product candidates. R7128, an oral treatment for chronic HCV infection, has ...
... CEST (7 a.m. PDT) on Friday, April 24. In an oral presentation, Anadys will present in vitro data ... ANA598 was administered as capsules at single oral doses of 400 mg, 800 mg, 1400 mg, 2000 mg (fed ... with the potential for once-daily or twice-daily oral dosing. In the preclinical program, ANA598 ...
... study showed boceprevir, its investigational oral hepatitis C protease inhibitor, in combination ... Annual Meeting; April 22-26, Copenhagen, Denmark; oral presentation, Abstract No. 4. 3. ... Annual Meeting; April 22-26, Copenhagen, Denmark; oral presentation, Abstract No. 126. 5. Reesink ...
... less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's ... of losing share upon the launch of either oral cladribine or fingolimod, as more physicians cite ...
... for Ophena(TM) , the most advanced estrogen-free oral therapy currently in development for the ... are being treated with either a 60mg once daily oral dose of Ophena(TM) or placebo over the 12-week ... receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary ...
... in postmenopausal patients when compared to oral delivery, a new study suggests. The study was ... activity before and after administration of oral or transdermal estrogen for a period of eight ... "a significant acceleration" of clotting after oral estrogen therapy, but no significant change after ...
... 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a ... III clinical trial to study the effects of an oral mTOR inhibitor in advanced RCC patients whose ... fungal infections should not receive Afinitor. oral ulceration is a common side effect with Afinitor. ...
... ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has ... (PK) and Pharmacodynamics (PD) of oral Insulin Formulations in Subjects with Type 2 ... will highlight the successful results from its oral insulin trials on type 2 diabetes patients ...
Vantia Therapeutics' Pipeline Continues to Mature
... has also initiated a new programme involving an oral plasma kallikrein inhibitor which may have ... vomiting and death by asphyxiation, and an oral treatment would be expected to provide ... as well as the off-label use of oral contraceptives. Vasopressin levels are raised in ...ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
... explanation that a Q1Q2 standard developed for oral solutions will nonetheless apply to Vancocin, an oral capsule product. Then, OGD backs off the ... new hurdles to the approvability of existing oral vancomycin ANDAs. For example, FDA's own data ...... to oxaliplatin. oral Picoplatin : In November, the Company announced ... results from a Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid ... dose-dependent plasma exposure when given by the oral route, indicating sufficient bioavailability to ...
DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
... patients could be successfully converted from oral opioids such as OxyContin(R) and from fentanyl ... chronic pain market including both patches and oral opioids." In addition to the recent Phase ... moderate to severe chronic pain from current oral (e.g., OxyContin(R)) and transdermal opioid ...... SGP ) Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were ... dose-ranging trial assessing both oral loading doses as well as maintenance doses of ... PCI was planned, and randomized to one of three oral loading doses of TRA (10mg, 20mg or 40mg) or ...
... a phase one clinical trial of AOBO-001, an oral capsule developed from traditional Chinese ... Company currently manufactures and markets the oral capsule in China under the Cease Enuresis oral Capsule brand, which was approved by China's ...
... NKTR-118, a peripheral opioid antagonist, is an oral once-a-day investigational drug to treat OIC, the ... or reversal of analgesia. There are no oral therapies to date that have demonstrated as much ... this heterogeneous population of patients." oral NKTR-118 combines Nektar's advanced small ...
Other ContentsheterotrophtagtagtagtagtagtagtagtaghishishishishishishishishishistonehistonehistonehistonehistonehistonehomeoboxhomeostasishomeostasishomeostasishomeostasisOther TagsTonesTones
(Date:12/3/2009)...llers must be included in the design of the upcomi...umanitarian crisis, according to a scientist at th...re , Dr Simon Lewis argues that at least 50% of th...n, known as REDD (Reducing Emissions from Deforest...wellers directly, and their property rights assure...
(Date:12/2/2009)...PHIA Children exposed to secondhand cigarette smo...r in adulthood, even if they never smoked. , Re...miology, Biomarkers & Prevention , a journal of th...t of a special tobacco focus in the December issue...s will be diagnosed with lung cancer; more than 15...
(Date:12/2/2009)...PHIA Mexican-American adolescents exposed to ciga...pick up the habit themselves, and this may be part...ing initiation, according to new study findings. ,...the United States and highlights the global implem...k Convention on Tobacco Control, which includes gu...
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Researchers determine predicting factors of positive lung cancer diagnoses in chest radiographs 47488 1Findings in epilepsy gene in animals may guide treatment directions for infants 47484 1Findings in epilepsy gene in animals may guide treatment directions for infants 47484 2Findings in epilepsy gene in animals may guide treatment directions for infants 47484 3Protein linked to mental retardation controls synapse maturation plasticity CSHL team finds 8676 1Protein linked to mental retardation controls synapse maturation plasticity CSHL team finds 8676 2Protein linked to mental retardation controls synapse maturation plasticity CSHL team finds 8676 3(Date:12/4/2009)...nhibOx, a leading developer of novel and effective...ned forces with MolPort, an innovator in rare chem...hemical trading platform and builds database of co...s database and its updates to computational chemis...irtual screening procedures. Once they identify su...
(Date:12/4/2009)...st-Selling author and Personal & Organizationa...Transformation through Accountability! , ...4, 2009 -- IMPAQ Accountability Business Consult...est-selling Author, renowned Speaker, and CEO &...ants Inc., will present at the 14th International ...
(Date:12/3/2009)...iropractic Traffic has gotten into the holiday spi...rketing tool. $1 gets chiropractors 3 months of un... Traffic is even including chiropractic promotiona... (PRWEB) December 3, 2009 -- Chiropractic Marke...tool. Chiropractic Marketing expertise provided b...
(Date:12/3/2009)...., Dec. 3 The development of Unive...MCPP) reached a milestone today with a "topping ou... construction at the new hospital that will replac..., (Photo: http://www.newscom.com/cgi-bin/prnh/... a steelworkers, tradition in which a steel beam c...
(Date:12/3/2009)... The American Medical A...tates District Court for the Southern District of ...reviously disclosed $350 million settlement that w...Health Group. ,, The action brought by the AMA,...ouri State Medical Association, along with several...
Breaking Medicine News(10 mins):Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3Health News:Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference 2Health News:New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 2Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 3Health News:'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro 4Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2[0] InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery [1] Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference [0] New Chiropractic Marketing: A $1 Chiropractic Marketing Tool that Can Make Users $1000s[0] 'Topping Out' Ceremony Marks Milestone in Construction of University Medical Center of Princeton at Plainsboro[0] Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court
RyansWashroomVirginiansTonesOmitUndernourishmentDeformabilityMidnightKateeNeedlessHamperingDevaluedMarginalisedScreaming
Other Tagsfish 2fish 3fish 4fish 5fish 6fish 7fish 8fish 9fish 10vision 2vision 3vision 4vision 5vision 6vision 7vision 8vision 9vision 10oils 2oils 3oils 4oils 5fats 2fats 3fats 4fats 5fats 6fats 7fats 8fats 9ring 2ring 3comparison 2comparison 3comparison 4comparison 5comparison 6comparison 7turn 2turn 3turn 4turn 5turn 6turn 7turn 8turn 9turn 10
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |